Fortrea (FTRE) vs. Its Rivals Head-To-Head Survey

Fortrea (NASDAQ:FTREGet Free Report) is one of 47 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its competitors? We will compare Fortrea to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, institutional ownership, dividends and earnings.

Profitability

This table compares Fortrea and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortrea -4.11% 4.76% 1.87%
Fortrea Competitors -3,338.19% -1,358.92% -41.93%

Analyst Ratings

This is a breakdown of recent ratings for Fortrea and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea 1 5 5 1 2.50
Fortrea Competitors 308 1204 2104 33 2.51

Fortrea presently has a consensus price target of $32.30, indicating a potential upside of 27.12%. As a group, “Medical laboratories” companies have a potential upside of 24.46%. Given Fortrea’s higher probable upside, research analysts plainly believe Fortrea is more favorable than its competitors.

Earnings and Valuation

This table compares Fortrea and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Fortrea $3.11 billion -$3.40 million -18.28
Fortrea Competitors $977.74 million -$121.96 million 4.68

Fortrea has higher revenue and earnings than its competitors. Fortrea is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

47.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 0.1% of Fortrea shares are owned by company insiders. Comparatively, 18.8% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Fortrea beats its competitors on 7 of the 12 factors compared.

Fortrea Company Profile

(Get Free Report)

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.